128 related articles for article (PubMed ID: 15171723)
1. Expression of an estrogen receptor variant lacking exon 3 in derivatives of MCF-7 cells with acquired estrogen independence or tamoxifen resistance.
Han F; Miksicek R; Clarke R; Conrad SE
J Mol Endocrinol; 2004 Jun; 32(3):935-45. PubMed ID: 15171723
[TBL] [Abstract][Full Text] [Related]
2. Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen.
Herman ME; Katzenellenbogen BS
J Steroid Biochem Mol Biol; 1996 Oct; 59(2):121-34. PubMed ID: 9010327
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells.
Madsen MW; Reiter BE; Larsen SS; Briand P; Lykkesfeldt AE
Cancer Res; 1997 Feb; 57(4):585-9. PubMed ID: 9044830
[TBL] [Abstract][Full Text] [Related]
4. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
5. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract][Full Text] [Related]
6. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
Morrissey JJ; Raney S
Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
[TBL] [Abstract][Full Text] [Related]
7. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
Pink JJ; Jordan VC
Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
[TBL] [Abstract][Full Text] [Related]
8. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
Lykkesfeldt AE; Madsen MW; Briand P
Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of estrogen receptor mRNA splice variants in the tamoxifen resistant human breast cancer cell line, MCF-7/TAMR-1 compared to the parental MCF-7 cell line.
Madsen MW; Reiter BE; Lykkesfeldt AE
Mol Cell Endocrinol; 1995 Apr; 109(2):197-207. PubMed ID: 7664983
[TBL] [Abstract][Full Text] [Related]
10. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
Miller MA; Lippman ME; Katzenellenbogen BS
Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
[TBL] [Abstract][Full Text] [Related]
12. Effects of an exon 5 variant of the estrogen receptor in MCF-7 breast cancer cells.
Rea D; Parker MG
Cancer Res; 1996 Apr; 56(7):1556-63. PubMed ID: 8603402
[TBL] [Abstract][Full Text] [Related]
13. An estrogen receptor-alpha splicing variant mediates both positive and negative effects on gene transcription.
Bollig A; Miksicek RJ
Mol Endocrinol; 2000 May; 14(5):634-49. PubMed ID: 10809228
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
Gökmen-Polar Y; Toroni RA; Hocevar BA; Badve S; Zhao Q; Shen C; Bruckheimer E; Kinch MS; Miller KD
Breast Cancer Res Treat; 2011 Jun; 127(2):375-84. PubMed ID: 20602165
[TBL] [Abstract][Full Text] [Related]
15. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
16. Alternative splicing of the estrogen receptor primary transcript normally occurs in estrogen receptor positive tissues and cell lines.
Pfeffer U; Fecarotta E; Arena G; Forlani A; Vidali G
J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):99-105. PubMed ID: 8603053
[TBL] [Abstract][Full Text] [Related]
17. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha.
Kinoshita Y; Chen S
Cancer Res; 2003 Jul; 63(13):3546-55. PubMed ID: 12839940
[TBL] [Abstract][Full Text] [Related]
18. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
19. Expression of estrogen receptor variants.
Fuqua SA; Allred DC; Auchus RJ
J Cell Biochem Suppl; 1993; 17G():194-7. PubMed ID: 8007697
[TBL] [Abstract][Full Text] [Related]
20. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.
Montano MM; Ekena K; Krueger KD; Keller AL; Katzenellenbogen BS
Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
